Cystic Fibrosis Foundation

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cystic Fibrosis Foundation
CFF Logo New.svg
FoundedDecember 16, 1955; 66 years ago (1955-12-16)[1]
Legal status501(c)(3) nonprofit organization[3]
FocusCystic fibrosis
Catherine C. McLoud[4]
Michael P. Boyle, M.D.[4]
Chair, Adult Advisory Council
KC White[5]
SubsidiariesCystic Fibrosis Patient Assistance Foundation, Cystic Fibrosis Foundation Therapeutics[2]
Revenue (2016)
Expenses (2016)$299,650,531[2]
Employees (2016)
Volunteers (2016)
Formerly called
National Cystic Fibrosis Research Foundation[6]

The Cystic Fibrosis Foundation (CFF) is a 501(c)(3) non-profit organization in the United States established to provide the means to cure cystic fibrosis (CF) and ensure that those living with CF live long and productive lives. The Foundation provides information about cystic fibrosis and finances CF research that aims to improve the quality of life for people with the disease. The Foundation also engages in legislative lobbying for cystic fibrosis.[7]


The Foundation was established in 1955 by a group of volunteers in Philadelphia, Pennsylvania.

In addition to providing grants for research into cystic fibrosis and supporting clinical trials, the foundation promotes and accredits 115 specialized centers for treatment of individuals with cystic fibrosis. The Foundation has over 80 chapters and offices across the United States.

Before it began using the current name, the organization was known as the "National Cystic Fibrosis Research Foundation".[6]

In 1989, scientists working for the Cystic Fibrosis Foundation discovered the gene that causes cystic fibrosis, considered the key to developing a cure for cystic fibrosis.

From 1982 until 1999, sports journalist Frank Deford served as chairman of the Foundation.

The Cystic Fibrosis Foundation has been a pioneer of cystic fibrosis treatment, having played a major role in the development and use of five FDA-approved therapies, including ivacaftor (Kalydeco).[7] The latest FDA approved drug is Trikafta, which was passed by the FDA in 54 days and is able to help up to 90% of CF patients.[8]

In 2014, the Cystic Fibrosis Foundation sold the rights to the royalties of the drugs for $3.3 billion, twenty times the Foundation's 2013 budget.[9][10]

In April 2022, the Foundation announced a $5 million investment to life science treatment company Sionna Therapeutics, for the development of a new cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a type of therapy that treats the underlying cause of CF. [11]

Present day[edit]

Currently the Foundation operates out of Bethesda, Maryland. Michael P. Boyle, M.D. is the active president and CEO of the organization.[12] At the end of 2019, Preston Campbell, M.D., retired as CEO.[13] The Foundation is devised into many different departments including Public Policy and Advocacy, Communications, and Fundraising. The Compass program is a service that provides patients and families with support for financial, legal, and insurance issues, particularly to get insurance coverage for the various medications they need to survive.[14]


The Foundation hosts several philanthropic events both locally around the chapters and nationwide. One of the biggest signature events is the Great Strides walk, established in 1989. It is a sponsored walk akin to Race for the Cure, where participants walk 10 kilometers (6.2 mi) to raise money to support research for cystic fibrosis. There are Great Strides walks in over 560 locations throughout the country. Great Strides has succeeded in raising over $180,000,000 for cystic fibrosis research.

Some other signature events include the CF Cycle for Life, CF Climb, Xtreme Hike, and Team CF. The list of national events includes Ultimate Golf Experience, American Airlines Celebrity Ski, and Volunteer Leadership Conference. Individual chapters may host their own events which may include, but are not limited to, fishing events, dinner dance events, golf tournaments, and finest events.[15]

The Foundation also hosts numerous advocacy events such as March on the Hill, state advocacy days, and Teen Advocacy Day allowing those with cystic fibrosis and their loved ones to speak their voice to those who represent them.[16]

In 2016, the Foundation hosted its first virtual event for adults with CF, BreatheCon.[17] The purpose of making the event virtual was to address the concerns of potential cross-infection among people living with cystic fibrosis who interact in person.[18] Since the first BreatheCon, the Foundation has hosted several other virtual events dedicated to connecting the community, including FamilyCon and ResearchCon.


  1. ^ "Cystic Fibrosis Foundation". Entity Search. Division of Corporations. Delaware Department of State. Retrieved May 6, 2018.
  2. ^ a b c d e f "Form 990: Return of Organization Exempt from Income Tax". Cystic Fibrosis Foundation. Guidestar. December 31, 2016.
  3. ^ "Cystic Fibrosis Foundation". Exempt Organization Search. Internal Revenue Service. Retrieved May 6, 2018.
  4. ^ a b "Board of Trustees". Cystic Fibrosis Foundation. Retrieved May 6, 2018.
  5. ^ "Advisory Council". Cystic Fibrosis Foundation. Retrieved May 6, 2018.
  6. ^ a b "Dorothy H. Andersen papers, 1930-1965".
  7. ^ a b "About the Cystic Fibrosis Foundation". Cystic Fibrosis Foundation. Retrieved 2013-02-19.
  8. ^ "FDA Approves Drug That Could Treat 90% of Cystic Fibrosis Patients". NBC New York. Retrieved 2021-09-03.
  9. ^ Andrew Pollack (November 19, 2014), "Deal by Cystic Fibrosis Foundation Raises Cash and Some Concern", New York Times, retrieved July 19, 2015
  10. ^ Joseph Walker; Jonathan D. Rockoff (November 19, 2014), Cystic Fibrosis Foundation Sells Drug's Rights for $3.3 Billion: The Biggest Royalty Purchase Ever Reflects Group's Share of Kalydeco Sales, Wall Street Journal, retrieved July 19, 2015
  11. ^ "Cystic Fibrosis Foundation Invests $5 Million in Sionna Therapeutics to Develop New CFTR Modulator Therapy". businesswire. 19 April 2022. Retrieved 29 April 2022.{{cite web}}: CS1 maint: url-status (link)
  12. ^ "Message from the President". Cystic Fibrosis Foundation. Archived from the original on 2006-10-25. Retrieved 2013-02-13.
  13. ^ Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "Preston W. Campbell, MD, President and CEO to Retire; Michael P. Boyle, MD, Appointed as Successor". Retrieved 2019-10-14.
  14. ^ Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "Compass Can Help". Retrieved 2019-10-14.
  15. ^ "Participate in an Event | CF Foundation". Archived from the original on 2015-09-05. Retrieved 2016-09-19.
  16. ^ Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "Advocate | CF Foundation". Retrieved 2019-10-14.
  17. ^ Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "BreatheCon: A Virtual Conference for Adults With CF". Retrieved 2020-09-29.
  18. ^ Henderson, Wendy. "The Danger of Cross Infections for Those Living With Cystic Fibrosis - Cystic Fibrosis News Today". Retrieved 2020-09-29.

External links[edit]